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Results: The impact of strictly switching all proton pump inhibitors 
to esomeprazole at admission resulted in a spillover “extra-cost” of 
€ 330.3 (95% CI, 276.1 to 383.8) thousand, whereas strictly switch-
ing to generic cetirizine resulted in savings of € 7.7 (95% CI, –11.1; 
–4.1) thousand. Over the entire study period, we estimated that the 
RDF resulted in “extra-costs” of € 503.6 (95% CI, 444.5 to 563.1) 
thousand.
Conclusion: Hospitals may contribute to increased overall health 
care costs if follow-on drugs are listed in the RDF. Therefore, health 
care providers and policy makers should be aware of the impact of 
evergreening strategies.
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Introduction: There have been variable measures introduced in 
Scotland in recent years to take advantage of the availability of gener-
ics in high volume classes. Consequently, there is a need to assess their 
influence to provide guidance to authorities for the future.
Patients (or Materials) and Methods: A mixture of retrospective 
observational studies and interrupted time series analyses on subse-
quent drug utilization (DDDs [defined daily doses]) and expenditure 
of the various drugs in the different classes. Only administrative data-
bases used. Demand side measures recorded and categorized by 4Es 
(education, engineering, economics, and enforcement).
Results: (1) Multiple demand-side measures led to low-cost generic 
proton pump inhibitors (PPIs) driving the increase in utilization in 
recent years. PPI expenditure in 2010 was 56% below 2001 levels 
despite a 3-fold increase in utilization. The multiple measures saved 
the Scottish NHS GB£159 mn in 2010. Similarly for the statins, 
expenditure in 2010 was only 7% above 2001 levels despite a 6.2-
fold increase in utilization. Savings through the multiple measures 
were estimated at GB£290 mn in 2010. There was also increasing 
utilization of higher strength statins following quality targets and 
SIGN guidance. (2) Expenditure on renin-angiotensin inhibitor drugs 
in 2007 was similar to 2001 with multiple reforms to limit utilization 
of angiotensin receptor blockers (ARBs). (3) No specific measures 
to enhance the prescribing of losartan (first ARB to lose its patent) 
versus other ARBs. This resulted in no change in the utilization 
of losartan postgenerics. (4) pragmatic approach to generic clopi-
dogrel resulted in continuing high INN prescribing for clopidogrel 
and associated savings. (5) Measures to encourage the prescribing 
of generic SSRIs versus escitalopram reduced SSRI expenditure, fall-
ing by 59% between 2001 and 2007, despite increased utilization. 
SSRI expenditure increased in countries with limited demand-side 
measures. (6) No change in the utilization of risperidone postgenerics 
with no specific measures encouraging its use versus other atypical 
antipsychotics (AAPs).
Conclusion: Multiple demand-side measures appreciably enhanced 
prescribing efficiency in Scotland. This was helped by high INN pre-
scribing rates (98% to 99% in all classes studied) and low costs for 
generics. There was no spillover effect between classes, even if closely 
related, to enhance the prescribing of generics first line where no 
active reforms (eg, losartan or risperidone). However, the complex-
ity of treating schizophrenia and bipolar disorders may limit the 
potential to enhance the prescribing of generic AAPs first line where 
appropriate.
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Introduction: Generic losartan has been available across Europe, 
providing opportunities for authorities to save costs as all angioten-
sin receptor blockers (ARBs) are seen as similar in treating hyper-
tension and heart failure at appropriate doses. However, initiatives 
vary across Europe. Consequently, there is a need to assess changes 
in losartan utilization versus other ARBs alongside accompanying 
demand-side measures to provide future guidance.
Patients (or Materials) and Methods: Retrospective observational 
study using an interrupted time series design of patients dispensed 
at least 1 ARB in Austria, Belgium, Denmark, England (Bury PCT), 
Scotland, Spain (Catalonia), and Sweden up to 3 years before generic 
losartan was reimbursed and to up 3 years after. Defined daily doses 
and only administrative databases were used. Demand-side measures 
were recorded under the 4Es (education, engineering, economics, and 
enforcement). Prices for generic losartan were also recorded.
Results: There was appreciable variation in health authority activity. 
This ranged from delisting of all other ARBs from the reimbursement 
list in Denmark; easing of prescribing restrictions for losartan but not 
for other ARBs in Austria and Belgium; and formularies, incentive 
programs, and therapeutic switching in NHS Bury and Sweden, to 
no targeted activities in Spain or Scotland (due to other activities and 
other ARBs shortly losing their patents). Significant changes were 
seen in losartan utilization in Denmark (losartan 93% of total ARBs 
by study end), NHS Bury (losartan 65% of total ARBs by the end of 
the study). However, no change in losartan utilization postgenerics 
until active measures) and Sweden (losartan 40% of total ARBs). 
